The claim that nasal spray delivers equivalent or superior levels to injection is not supported by published data and is not a claim any legitimate researcher has made in print
#CiplaAt90 #CaringforLife Cipla has the rights to distribute and promote Yurpeak, a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, indicated as an adjunct to diet and exercise for the treatment of type 2 diabetes and chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity
These findings may have important clinical implications for the treatment of diseases in elderly humans that are linked to increased oxidative stress
Each location has distinct absorption characteristics: the abdomen typically shows the fastest and most predictable uptake due to consistent subcutaneous tissue depth and blood flow patterns
If you experience these, follow your diabetes team's advice on managing low blood sugar, typically involving consuming fast-acting carbohydrates
This minimal dose activates GLP-1 receptors in your brain without overwhelming your system, reducing the likelihood of severe nausea in the first week